Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors

Abstract

Conclusion The use of mTOR inhibitors is associated with a small but higher risk of FAEs (fatal adverse events)  compared to control patients. In the appropriate clinical scenario, the use of these drugs remains justified in their approved indications.